

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address COMMISSIONER OF PATENTS AND TRADEMARKS
Washington D C 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
09/431,469	11/01/1999	DAVID M. ARMISTEAD	VPI/95-09-DI	8756	
75	90 03/20/2003				
JAMES F HALEY JR FISH & NEAVE 1251 AVENUE OF THE AMERICAS			EXAM	EXAMINER MORAN, MARJORIE A	
			MORAN, MA		
NEW YORK, I	NY 100201104	DAVID M. ARMISTEAD VPI/95-09-DI	PAPER NUMBER		
			1631		
			DATE MAILED: 03/20/2003	25	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)		
	•	09/431,469	ARMISTEAD ET AL.		
Office Action Summary		Examiner	Art Unit		
		Marjorie A. Moran	1631		
	he MAILING DATE of this communication app		correspondence address		
Period for R	• •				
THE MAI - Extension after SIX (- If the peric - If NO peric - Failure to - Any reply	TENED STATUTORY PERIOD FOR REPLY ILING DATE OF THIS COMMUNICATION. Is of time may be available under the provisions of 37 CFR 1.13 (6) MONTHS from the mailing date of this communication. In odd for reply specified above is less than thirty (30) days, a reply od for reply is specified above, the maximum statutory period we reply within the set or extended period for reply will, by statute, received by the Office later than three months after the mailing tent term adjustment. See 37 CFR 1.704(b).	6(a). In no event, however, may a reply be to within the statutory minimum of thirty (30) da ill apply and will expire SIX (6) MONTHS from cause the application to become ABANDON	imely filed sys will be considered timely. In the mailing date of this communication. ED (35 U.S.C. § 133).		
	esponsive to communication(s) filed on 17 C	october 2002			
		s action is non-final.			
/ <u> </u>	ince this application is in condition for allowa		prosecution as to the merits is		
	osed in accordance with the practice under E				
4)⊠ Cla	aim(s) 19-30 is/are pending in the application	٦.			
4a)	Of the above claim(s) is/are withdraw	n from consideration.			
5) Cla	aim(s) is/are allowed.				
6)⊠ Cla	aim(s) <u>19-30</u> is/are rejected.				
7) <u></u> Cla	aim(s) is/are objected to.				
8) <u></u> Cla	aim(s) are subject to restriction and/or	election requirement.			
Application	Papers				
9) <u></u> The	specification is objected to by the Examiner				
10)⊠ The	drawing(s) filed on <u>01 November 1999</u> is/are	e: a)⊠ accepted or b)□ objected	to by the Examiner.		
A _l	pplicant may not request that any objection to the	drawing(s) be held in abeyance. S	See 37 CFR 1.85(a).		
11) <u></u> The	proposed drawing correction filed on	is: a) ☐ approved b) ☐ disappr	oved by the Examiner.		
_	approved, corrected drawings are required in rep				
12) <u></u> The	oath or declaration is objected to by the Exa	ıminer.			
Priority unde	er 35 U.S.C. §§ 119 and 120				
13) <u></u> Ac⊦	knowledgment is made of a claim for foreign	priority under 35 U.S.C. § 119(a	a)-(d) or (f).		
a) <u></u> A	II b)☐ Some * c)☐ None of:				
1.[Certified copies of the priority documents	have been received.	J		
2.	2. Certified copies of the priority documents have been received in Application No				
3.[* See	Copies of the certified copies of the priori application from the International Burthe attached detailed Office action for a list of	eau (PCT Rule 17.2(a)).	_		
14)∏ Ackn	owledgment is made of a claim for domestic	priority under 35 U.S.C. § 119(e) (to a provisional application).		
	The translation of the foreign language proviously the translation of the foreign language proviously.	• •			
Attachment(s)					
2) Notice of I	References Cited (PTO-892) Draftsperson's Patent Drawing Review (PTO-948) on Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal	y (PTO-413) Paper No(s). <u>23,24</u> . Patent Application (PTO-152)		
J.S. Patent and Tradema PTO-326 (Rev. 04	·	ion Summary	Part of Paper No. 25		

Application/Control Number: 09/431,469

Art Unit: 1631

In view of the new rejections set forth below, the finality of the office action sent 7/17/02 is hereby withdrawn. Further, the indication of allowability of claims 25-30 is also withdrawn in view of the rejections set forth below. The examiner regrets any confusion and urges applicants to review the Trilateral Project WM4 Report on Comparative Study on Protein 3-Dimensional (3-D) Structure Related Claims at: http://www.uspto.gov/web/tws/wm4/wm4_3d/report.htm for a complete analysis of patentability issues with regard to claims reciting crystallographic coordinates. The examiner considers point A4 in the US notes regarding Cases 6 and 7 to be especially relevant.

Any rejections and objections not set forth below are hereby withdrawn. The amendment filed 10/17/02 has been entered. A nonfinal office action on the merits of pending claims 19-30 follows.

Drawings

The drawings have been approved by the draftsperson.

35 USC § 101/112

The claims are directed to methods of identifying compounds which bind to calcineurin; i.e. *in silico* screening methods that have a practical application, and are therefore statutory under 35 USC 101. The specification discloses on pages 2-3 that compounds which bind to a phosphatase binding site and/or an FK506/FKB12 binding site may inhibit the phosphatase activity of calcineurin. The specification further discloses, on pages 1 and 3, a correlation between inhibitors of calcineurin and the utility of such compounds as immunosuppressants. As the utility of the method is based

Application/Control Number: 09/431,469

Art Unit: 1631

on the utility of the compounds identified, and the specification sets forth a credible utility for such compounds, the claims have utility under 35 USC 112.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 19-25 are rejected under 35 U.S.C. 103(a) as being unpatentable over HENDRY et al. (US 5,705,335).

HENDRY teaches a method to evaluate the ability of a chemical compound to associate with another (the "degree of fit" of binding to a pharmacophore) wherein a ligand is docked (fitting operation) into a binding site, and the results evaluated (col. 7,

Application/Control Number: 09/431,469

Art Unit: 1631

lines 9-24). HENDRY also teaches "outputting" results of his fitting method (Figures 1-4). HENDRY further teaches that compounds identified using a computer modeling/docking algorithm may be synthesized (col. 10, lines 17-21) and evaluated for binding in in vitro assays (col. 10, line 40-col. 11, line 64), thereby making obvious all of the steps of the claimed methods. It is noted that the structure coordinates recited in the claims are nonfunctional descriptive material as they do not impose a change on the processing steps used in the claimed methods. Algorithms to fit or dock a molecular entity into a binding site of a molecule or molecular complex are known in the art, as set forth above. A method of using a known algorithm for its known purpose does not become nonobvious merely because new data is available for analysis. Nonfunctional descriptive material cannot render non-obvious an invention that would have otherwise been obvious. See In re Gulack, 703 F.2d 1381, 1385 (Fed. Cir. 1983) and MPEP 2106. Applicant is also directed to the Trilateral Project WM4 Report on Comparative Study on Protein 3-Dimensional (3-D) Structure Related Claims at: http://www.uspto.gov/web/tws/wm4/wm4 3d/report.htm>

Conclusion

Claims 19-30 are rejected.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Marjorie A. Moran whose telephone number is (703)

Application/Control Number: 09/431,469 Page 5

Art Unit: 1631

305-2363. The examiner can normally be reached on Monday to Friday, 7:30 am to 4 pm EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Woodward can be reached on (703) 308-4028. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4242 for regular communications and (703) 872-9306 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 305-3524.

MARJORIE MORAN

PATENT EXAMINER

Mayoria a Moran

11 IN 10

mam March 14, 2003

MICHAEL P. WOODWARD SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600